Literature DB >> 30852744

Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?

James Milner1, Rafaela Nicolau Teixeira2, Ana Vera Marinho3, Nuno Silva4, Suzana Calretas4, José Ferrão4, Emanuel Furtado4, Maria João Telo3, Miguel Ventura3, João Cristóvão3, Luís Elvas3, Guilherme Mariano Pêgo3, Natália António3,2.   

Abstract

BACKGROUND: Despite the important role of cardiac pacing in preventing syncope and sudden cardiac death in familial amyloid polyneuropathy (FAP), we lack clear guidelines as to the ideal timing and indications for permanent pacemaker implantation.
PURPOSE: The purpose of this study was to evaluate the ideal timing for pacemaker implantation in FAP patients submitted to liver transplantation.
METHODS: Retrospective study of 258 FAP patients submitted to liver transplantation between 1992 and 2012. Comparison of three groups: (A) patients without pacemaker (N = 122); (B) patients submitted to pacemaker implantation after liver transplantation, with documented conduction disorders (N = 73); and (C) patients submitted to "prophylactic" pacemaker implantation before transplantation, (N = 73). Patients were followed up for 12.2 ± 6.7 years.
RESULTS: The majority of patients (57%) were referred for pacemaker implantation, which occurred before liver transplantation in 50% of cases. Patients who required pacemaker after transplantation presented significantly higher Machado-Joseph Score during pre-transplant evaluation than those who did not require pacemaker (24 ± 10 vs 20 ± 10, p = .025), and also exhibited higher levels of hepatic cytolysis enzymes and hyperbilirubinemia. The most common indication for permanent pacemaker was first degree atrioventricular block, with a mean time between transplantation and pacemaker implantation of 8.7 ± 4.2 years. During long-term follow-up, all-cause mortality was 27% and was lowest in the group submitted to pacemaker implantation only after liver transplantation (p = 0.002).
CONCLUSION: The majority of FAP patients submitted to liver transplantation will need a pacemaker at some time of follow-up. However, it seems that there is no benefit in "prophylactic" cardiac pacing before liver transplantation.

Entities:  

Keywords:  Amyloid polyneuropathies; Artificial; Cardiac conduction defect; Familial; Pacemaker; Polyneuropathy

Mesh:

Year:  2019        PMID: 30852744     DOI: 10.1007/s10840-019-00517-y

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  14 in total

1.  A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves.

Authors:  C ANDRADE
Journal:  Brain       Date:  1952-09       Impact factor: 13.501

2.  Prophylactic pacemaker implantation in familial amyloid polyneuropathy.

Authors:  Vincent Algalarrondo; Sylvie Dinanian; Christophe Juin; Denis Chemla; Soumiya L Bennani; Claude Sebag; Violaine Planté; Dominique Le Guludec; Didier Samuel; David Adams; Michel S Slama
Journal:  Heart Rhythm       Date:  2012-03-03       Impact factor: 6.343

Review 3.  Transthyretin-related familial amyloidotic polyneuropathy.

Authors:  Yukio Ando; Masaaki Nakamura; Shukuro Araki
Journal:  Arch Neurol       Date:  2005-07

4.  Progression of myocardial sympathetic denervation assessed by 123I-MIBG imaging in familial amyloid polyneuropathy and the effect of liver transplantation.

Authors:  Maria da Conceição Azevedo Coutinho; Nuno Cortez-Dias; Guilhermina Cantinho; Isabel Conceição; Tatiana Guimarães; Gustavo Lima da Silva; Miguel Nobre Menezes; Ana Rita Francisco; Rui Plácido; Fausto J Pinto
Journal:  Rev Port Cardiol       Date:  2017-05-04       Impact factor: 1.374

5.  Heart complications in familial transthyretin amyloidosis: impact of age and gender.

Authors:  Rolf Hörnsten; Johanna Pennlert; Urban Wiklund; Per Lindqvist; Steen M Jensen; Ole B Suhr
Journal:  Amyloid       Date:  2010-06       Impact factor: 7.141

6.  Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients.

Authors:  Rolf Hörnsten; Urban Wiklund; Bert-Ove Olofsson; Steen M Jensen; Ole B Suhr
Journal:  Transplantation       Date:  2004-07-15       Impact factor: 4.939

Review 7.  Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.

Authors:  Morie A Gertz; Merrill D Benson; Peter J Dyck; Martha Grogan; Terresa Coelho; Marcia Cruz; John L Berk; Violaine Plante-Bordeneuve; Hartmut H J Schmidt; Giampaolo Merlini
Journal:  J Am Coll Cardiol       Date:  2015-12-01       Impact factor: 24.094

8.  Recent advances in the treatment of familial amyloid polyneuropathy.

Authors:  David Adams
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

9.  The heart in Portuguese amyloidosis.

Authors:  A F de Freitas
Journal:  Postgrad Med J       Date:  1986-06       Impact factor: 2.401

10.  Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years.

Authors:  S Yamamoto; H E Wilczek; G Nowak; M Larsson; A Oksanen; T Iwata; H Gjertsen; G Söderdahl; L Wikström; Y Ando; O B Suhr; B-G Ericzon
Journal:  Am J Transplant       Date:  2007-09-14       Impact factor: 8.086

View more
  3 in total

Review 1.  Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.

Authors:  Deepa M Gopal; Frederick L Ruberg; Omar K Siddiqi
Journal:  Curr Heart Fail Rep       Date:  2019-10

Review 2.  Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.

Authors:  Hiroyuki Yamamoto; Tomoki Yokochi
Journal:  ESC Heart Fail       Date:  2019-09-25

3.  Domino living donor liver transplantation of familial amyloid polyneuropathy patient - A case report.

Authors:  Sungrok Cha; Jiwon Kim; Soo Joo Choi; Gaab Soo Kim
Journal:  Anesth Pain Med (Seoul)       Date:  2020-10-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.